SHANGHAI--(BUSINESS WIRE)--EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California between April 5-10, 2024.
This presentation will highlight the preclinical results for EMB-07, a novel ROR1 targeting TCE designed with an optimized efficacy, safety and pharmacokinetic profile. Furthermore, the presentation will discuss the TCE’s differentiated in vitro potency relative to benchmark molecules constructed using different modalities. The presentation details are as follows:
Title: Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
Session Date: April 8, 2024
Session Time: 9:00AM – 12:30PM local time
Presentation number: LB126 (poster section 52, number 14)
“With EMB-07 EpimAb is applying a unique and proprietary approach to target ROR1, a protein expressed on the surface of a multitude of solid and liquid tumor cells,” Dr. Chengbin Wu, Founder and CEO of EpimAb commented. “We are very excited to share the preliminary preclinical findings for this bispecific at the AACR Annual Meeting, and look forward to further unlocking the potential of our T-cell engager and bispecific antibody platforms to target diseases with unmet need and help patients around the world.”
About EMB-07
EMB-07 is a novel ROR1×CD3 T-cell engaging bispecific antibody developed based on EpimAb’s proprietary bispecific antibody platforms. This molecule was carefully designed for an optimized efficacy and safety profile, as demonstrated by only modest levels of cytokine release in preclinical studies. EMB-07 is currently being evaluated in a Phase I trial in solid tumors and lymphomas (NCT05607498; CTR20230350).
About EpimAb Biotherapeutics Inc
EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com
